Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
DSM Mulls Sale Of Polymer Units
by Alex Scott
November 10, 2014
| A version of this story appeared in
Volume 92, Issue 45
DSM is considering strategic options—including divestment—of its polymer intermediates business, which manufactures composite resins, caprolactam, and acrylonitrile. The unit has annual sales of about $1.9 billion. The move follows pressure from the activist hedge fund Third Point, which has taken a stake in DSM and wants to see the firm broken up. Third Point is similarly targeting Dow Chemical. The pretax profits of the polymer intermediates business fell $6 million, to $29 million, for the third quarter of 2014.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter